Taysha Gene Therapies, Inc. (TSHA): Capital Expenditures
$738.0K
Year ended 2025-12-31
$381.0K
Trailing 12 months to 2026-06-30
-67.0%
3-year compound annual growth
+55.2%
5-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $738.0K | +97.3% | 2026-03-19, From 2025-01-01 |
| 2024-12-31 | $374.0K | -90.3% | 2026-03-19, From 2024-01-01 |
| 2023-12-31 | $3.87M | -81.2% | 2025-02-26, From 2023-01-01 |
| 2022-12-31 | $20.62M | +34.7% | 2024-03-19, From 2022-01-01 |
| 2021-12-31 | $15.30M | n/m | 2023-03-28, From 2021-01-01 |
| 2020-12-31 | $82.0K | n/a | 2022-03-31, From 2020-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Taysha Gene Therapies, Inc. (TSHA) | 2025-12-31 | $738.0K | +97.3% |
| Alpha Cognition Inc. (ACOG) | 2025-12-31 | $293.5K | +999.2% |
| TScan Therapeutics, Inc. (TCRX) | 2025-12-31 | $4.41M | +15.2% |
| Caribou Biosciences, Inc. (CRBU) | 2025-12-31 | $1.36M | -72.2% |
| Fate Therapeutics Inc (FATE) | 2025-12-31 | $5.95M | +715.5% |
| Lineage Cell Therapeutics, Inc. (LCTX) | 2025-12-31 | $522.0K | -7.6% |
| Relay Therapeutics, Inc. (RLAY) | 2025-12-31 | $410.0K | -79.7% |
| Pelthos Therapeutics Inc. (PTHS) | 2025-12-31 | $99.0K | n/a |
| DBV Technologies S.A. (DBVT) | 2025-12-31 | $532.0K | -77.2% |
Compare TSHA, ACOG, TCRX, CRBU side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗